International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Inclusion criteria: * newly diagnosed lymphoblastic lymphoma * age \<18 years * patient enrolled in a participating center * written informed consent of patient (\>14 years of age or according to local law and regulation) and parents to trial participation and transfer and processing of data * willingness of patients and the investigator/pathologist to provide adequate slides/blocks for reference (molecular) pathology and international pathology panel and/or fresh or fresh frozen samples for genetic risk group stratification if these samples are available after standard diagnostic procedures. Exclusion criteria: * lymphoblastic lymphoma as secondary malignancy * non-lymphoma related relevant medical, psychiatric or social conditions incompatible with trial treatment, including among others * prior organ transplant * severe immunodeficiency * demyelinating Charcot-Marie Tooth syndrome * serious acute or chronic infections, such as HIV, VZV and tuberculosis * urinary tract infection, cystitis, urinary outflow obstruction, severe renal impairment (creatinine clearance less than 20 ml/min) * severe hepatic impairment (bilirubin \>3 times ULN, transaminases \>10 times ULN) * myocardial insufficiency, severe arrhythmias * ulcers of the oral cavity and known active gastrointestinal ulcer disease * known hypersensitivity to any IMP and to any excipient (listed in section 6.1 of the respective SmPC) * steroid pre-treatment with ≥ 1 mg/kg/d for more than two weeks…